amphotericin B liposomal (Ambisome)
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Central Line Fungal Infections
Conditions
Central Line Fungal Infections
Trial Timeline
Sep 1, 2006 → Sep 1, 2010
NCT ID
NCT00936910About amphotericin B liposomal (Ambisome)
amphotericin B liposomal (Ambisome) is a approved stage product being developed by Astellas Pharma for Central Line Fungal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00936910. Target conditions include Central Line Fungal Infections.
What happened to similar drugs?
3 of 19 similar drugs in Central Line Fungal Infections were approved
Approved (3) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00936910 | Approved | Completed |
Competing Products
20 competing products in Central Line Fungal Infections